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1. Introduction
Tuberculosis is a chronic infectious disease, which is
seriously harmful to human health. Jinshuibao capsule
is a kind of clinical drugs, which is commonly used to
protect liver, kidney and other organs. The clinical effect
of Jinshuibao capsule combined treatment on newly
diagnosed pulmonary tuberculosis was analyzed in this
paper. The results are reported as follow.
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2. Materials and methods
2.1. Clinical data
62 cases of newly diagnosed pulmonary tuberculosis
patients, who were treated in our hospital from January
2013 to January 2014, were served as the object of study. All
the patients were diagnosed as pulmonary tuberculosis by
clinical examination, conformed to the diagnostic criteria
developed by National tuberculosis prevention and control
work academic conference in 1982. Their hospitalization
time was above two months. The patients were divided
into control group and treatment group randomly, 31
cases in each group. Among them, the control group had
16 males and 15 females, the patient’s age was ranged
from 18 to 72 years old, with the mean of (44.5 ± 15.4)
years old, there were 9 cases of V pulmonary tuberculosis,
31 cases of III pulmonary tuberculosis and 1 case of II
pulmonary tuberculosis. The treatment group had 15 males
and 16 females, the patient’s age were ranged from 20 to
Analysis on Effect of Jinshuibao Capsule 
Combined Treatment on Newly Diagnosed 
Pulmonary Tuberculosis
Xinmin Yu*
The People’s Hospital of Lengshuijiang City, Lengshuijiang, Hunan 417500, China
KEYWORDS
Jinshuibao capsule
Combined treatment
Newly diagnosed pulmonary 
tuberculosis
ABSTRACT Objective: To discuss the clinical effect of jinshuibao capsule 
combined treatment on newly diagnosed pulmonary tuberculosis. Method: 
62 cases of newly diagnosed pulmonary tuberculosis patients, who were treated 
in our hospital from January 2013 to January 2014, were served as the object 
of study. They were randomly divided into control group and treatment group. 
Patients in the control group received a single 2SHRZ/4HR chemotherapy, while 
the treatment group received jinshuibao capsule combined treatment on the 
base of control group. The improvement of clinical symptoms, chest X-ray film 
and laboratory examination results of both groups were compared and analysed. 
Results: The total effective rate of clinical treatment, lesion absorption, sputum 
negative conversion and improvement rate of clinical symptom of treatment 
group was obviously better than the control group. The difference of clinical 
effect between two groups was statistically significant (p  < 0.05). Conclusion: 
Jinshuibao capsule combined treatment has  satisfactory clinical effect on newly 
diagnosed pulmonary tuberculosis.
 CLINICAL THERAPY
2 Volume 5 Issue 3  | September 2016 | Xinmin Yu
70 years old, and the mean was (46.5 ± 11.5) years old, 
there were 9 cases of V pulmonary tuberculosis, 30 cases 
of III pulmonary tuberculosis, 2 cases of II pulmonary 
tuberculosis. There was no statistical difference in clinical 
data between two groups (p > 0.05).
2.2. Methods
Both groups were treated with 2SHRZ/4HR chemotherapy. 
For patients with S allergies, E treatment was given, that 
was, patients were treated with pyrazinamide Z, rifampicin 
R, isoniazid H and streptomycin S during the first two 
months of treatment, followed by ethambutol E in the later 
four months. Usage and dosage of drug in the two schemes 
are the same. On this basis, the treatment group received 
oral treatment of Jinshuibao capsule, produced by Jiangxi 
Jinshuibao Pharmaceutical Co., Ltd, 5 capsules each time, 3 
times a day after each meal.
2.3. Observation index
Firstly, chest X-ray film was conducted to inspect lesions 
absorption of patients. Lesions absorption referred to that 
the chest X-ray film examination confirmed that the lesion 
cavity was closed or the absorption rate of more than 50%. 
Secondly, improvement of clinical symptoms of patients 
was observed, such as anorexia, cough, night sweats, fever 
and other symptoms. Thirdly, sputum negative conversion 
situation of both groups was examined [1]. Fourthly, 
the total effective rate of clinical treatment of patients in 
both groups was determined. Cure referred to there was 
no active lesions found on chest X-ray film after clinical 
treatment, sputum negative conversion time was more than 
one year, related clinical symptoms completely disappeared 
and the lesion was relatively stable after one year of follow-
up. Improvement implied that the lesion was significantly 
reduced or the cavity was closed after the clinical treatment, 
result of sputum test was negative and the related clinical 
symptoms disappeared. Invalid indicated that there was 
no change in the results of chest X-ray and sputum test 
after clinical treatment. Total Effective Rate = (Cure + 
Improvement) / Total of Cases × 100% [2].
2.4. Statistical treatment
The medical research data were statistically analyzed 
by SPSS 17.0 software. (x ± s) was used to express the 
measurement data, a comparative analysis of the data was 
made by single factor analysis of variance, and use X2 test 
to do statistical analysis on count data, if p  < 0.05, the 
difference between data is statistically significant [3].
3. Results
After one month of clinical treatment, in the treatment
group, the improvement rate of symptoms such as cough,
expectoration, anorexia, fatigue, night sweats, low-grade fever
and other symptoms was 80%. After 3 months of treatment,
the improvement rate of clinical symptom was 100%. While
in the control group, after one month of clinical treatment, the
improvement rate of symptoms such as cough, expectoration,
anorexia, fatigue, night sweats, low-grade fever and other
symptoms was 50%. After 3 months of treatment, the
improvement rate was 80%. There was statistical difference
in the improvement rate of symptoms between two groups
(p < 0.05). For the sputum negative conversion rate, after
one, three and six months of clinical treatment, the value in
the treatment group was 50%, 70% and 90% respectively;
while the value in the control group was 20%, 50% and 70%
respectively. There was statistical difference in the sputum
negative conversion rate between two groups (p < 0.05). The
absorption rate of lesions was 94% in the treatment group, while
the absorption rate of lesions was 74% in the control group. There 
was statistical difference in the absorption rate of lesions between 
two groups (p < 0.05). In the treatment group, the total effective
rate of clinical treatment was 96.77%; whereas in the control
group, the total effective rate of clinical treatment was 41.91%.
There was statistical difference in the total effective rate of clinical 
treatment between two groups (p < 0.05). The results were shown 
in Table 1.
4. Conclusions
When an individual is infected with Mycobacterium
tuberculosis, immunity is an important factor to determine
the occurrence and development of tuberculosis. Cell
immunity that mediated by T lymphocyte is mainly
responsible for tuberculosis immunity. Furthermore,
humoral immunity also plays a certain role. The study
showed that patients with pulmonary tuberculosis will
have an abnormal cellular immune function, CD 4+ T
lymphocyte decreased, CD 8+ T lymphocyte increased,
CD 4+/ CD 8+ ratio decreased or even inverted. In fact, NK
cells can optimize CD 8+ T cells to produce 7-interferon
and engulf cells that are infected with Mycobacterium 
Table 1. Comparison and analysis of clinical effects between two groups of patients with pulmonary tuberculosis (n%).
Group Case (n) Cure Improvement Invalid Total Effective Rate
Treatment  group 31 29 (93.55%) 1 (3.23%) 1 (3.23%) 30 (96.77%)
Control group 31 12 (38.71%) 1 (3.23%) 18 (58.06) 13 (41.91%)
χ2 / 4.36 / 12.18 4.08
P value / <0.05 / <0.05 <0.05
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tuberculosis , thus, playing a key role in innate immunity 
against TB [4,5]. Also, B cells can reduce the inflammatory 
response in patients with pulmonary tuberculosis and 
enhance the containment of Mycobacterium tuberculosis . 
In the research, there was no difference in the levels 
of B cells, NK cells, CD 4+, CD 8+ and CD 4+/CD 8+ 
between two groups before treatment. After application 
of Jinshuibao capsule, compared with the control group, 
B cells, NK cells and CD 4+ levels of the treatment 
group were elevated, CD 8+ level decreased, CD 4+/CD 
8+ elevated. Hence, Jinshuibao capsule can improve the 
cellular immune function of patients with pulmonary 
tuberculosis. The CD 4+ cells was decreased, the function 
producing lymph nodes, stimulating B cells to produce 
IgG, IgA, IgM antibody and helping other lymphocytes 
weaken, suggesting that the immune function is low. The 
decrease of CD 4 cells that resulted from the weakening of 
cellular immunity of patients with pulmonary tuberculosis 
would affect the level of IgM, IgA and IgG [6]. However, 
some scholars believe that the level of humoral immunity 
in tuberculosis patients is elevated, playing a role in the 
immune process of pulmonary tuberculosis.
   Jinshuibao capsule is a kind of drug, which is produced 
artificially by isolation from aweto, followed by fermentation 
and purification process.. The main chemical components 
include 19 amino acid, such as mannitol, uracil, adenine, 
adenosine, etc. Besides, it is composed of variety of vitamins, 
selenium, zinc and other trace elements. The satisfactory 
clinical effect of Jinshuibao capsule in treatment of newly 
diagnosed pulmonary tuberculosis is mainly attributed to 
several drug action mechanisms. Firstly, it helps to improve 
the tolerance of patients to drug chemotherapy, improve 
the adverse reactions symptoms, provide protective effects 
on the function of important organs such as liver and 
kidney, reduce DNA damage, gives protective effects on the 
function and structure of cell membrane, prevent calcium 
influx and improve the lipid metabolism of cell membrane. 
Jinshuibao capsule gives similar detoxification effect as other 
types of drugs, especially for anti-tumor drugs. Secondly, it 
can improve phagocytic ability of macrophage-monocyte 
system, protect cellular immunity. Patients with pulmonary 
tuberculosis will have varying degree of decreased cellular 
immunity. Although the conventional BCG, transfer factor 
and levamisole give certain curative effect, treatment cost and 
incidence of adverse reactions after the treatment are much 
higher. So, the clinical application is limited. Meanwhile, 
the killing ability of Jinshuibao capsule on Mycobacterium 
tuberculosis and phagocytic ability on macrophage is strong. 
Moreover, there is no obvious toxic side effect and the cost of 
treatment is lower. Therefore, patients are readily to accept, 
making higher clinical application value. Thirdly, in addition 
to the conventional effects of anti-asthmatic, expectorant 
and antitussive, Jinshuibao capsule gives the effects of strong 
nourishing, hypnotic and sedative as well as the ability of 
regulating and improving the body’s energy metabolism, 
consequently prompting the body recovery and effectively 
controlling the clinical symptoms.
   Domestic studies prove that cytokines might be involved 
in the immune response of tuberculosis. TNF-α is produced 
by monocytes, macrophages and lymphocytes, which promote 
macrophage activation, thus enhancing its phagocytosis. 
Also, it is involved in the formation of granuloma and it 
can play a protective role in Mycobacterium tuberculosis 
infection. IFN-γ is an immune regulatory factor secreted by 
Th1 cells. It can activate monocytes and control the spread of 
infection. At the same time, it enhances the bactericidal effect 
of macrophages, plays an important role in anti-tuberculosis 
immunity. sIL-2R is a kind of important immune inhibitory 
substance. It can inhibit the proliferation of T cells, weaken the 
immune response of IL-2, causing NK cell, which is an effector 
cell of IL-2, difficult to maintain its natural killer activity. IL-
10 acts as a suppressor cell factor, if it is over secreted, chronic 
and recurrent Mycobacterium tuberculosis infection could be 
promoted [7].
   In conclusion, Jinshuibao capsule combined therapy has 
satisfactory clinical effect on newly diagnosed pulmonary 
tuberculosis, lower adverse reactions and higher control 
rate of clinical symptom. Hence, it provides high clinical 
application value.
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